319 related articles for article (PubMed ID: 25305590)
1. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
[TBL] [Abstract][Full Text] [Related]
2. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.
Yerlikaya A; Okur E; Ulukaya E
Tumour Biol; 2012 Oct; 33(5):1385-92. PubMed ID: 22477712
[TBL] [Abstract][Full Text] [Related]
3. Data for a proteomic analysis of p53-independent induction of apoptosis by bortezomib.
Yerlikaya A; Okur E; Tarık Baykal A; Acılan C; Boyacı İ; Ulukaya E
Data Brief; 2014 Dec; 1():56-9. PubMed ID: 26217687
[TBL] [Abstract][Full Text] [Related]
4. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Yerlikaya A; Erin N
Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
[TBL] [Abstract][Full Text] [Related]
5. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
Yerlikaya A; DoKudur H
Mol Biol (Mosk); 2010; 44(5):859-66. PubMed ID: 21090173
[TBL] [Abstract][Full Text] [Related]
7. Expression of heme oxygenase-1 in response to proteasomal inhibition.
Yerlikaya A
Protein Pept Lett; 2012 Dec; 19(12):1330-3. PubMed ID: 22670665
[TBL] [Abstract][Full Text] [Related]
8. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Yu J; Tiwari S; Steiner P; Zhang L
Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
10. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Ling YH; Liebes L; Zou Y; Perez-Soler R
J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
[TBL] [Abstract][Full Text] [Related]
11. Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function.
Zhu Z; Ramos J; Kampa K; Adimoolam S; Sirisawad M; Yu Z; Chen D; Naumovski L; Lopez CD
J Biol Chem; 2005 Oct; 280(41):34473-80. PubMed ID: 16091363
[TBL] [Abstract][Full Text] [Related]
12. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
13. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
14. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
16. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
An WG; Hwang SG; Trepel JB; Blagosklonny MV
Leukemia; 2000 Jul; 14(7):1276-83. PubMed ID: 10914553
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
Nikiforov MA; Riblett M; Tang WH; Gratchouck V; Zhuang D; Fernandez Y; Verhaegen M; Varambally S; Chinnaiyan AM; Jakubowiak AJ; Soengas MS
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19488-93. PubMed ID: 18042711
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Cascone T; Morelli MP; Morgillo F; Kim WY; Rodolico G; Pepe S; Tortora G; Berrino L; Lee HY; Heymach JV; Ciardiello F
J Cell Physiol; 2008 Sep; 216(3):698-707. PubMed ID: 18381602
[TBL] [Abstract][Full Text] [Related]
20. A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis.
Okur E; Yerlikaya A
Cell Biol Toxicol; 2019 Feb; 35(1):33-47. PubMed ID: 29948483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
